These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 16203777)

  • 1. Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.
    Stein T; Price KN; Morris JS; Heath VJ; Ferrier RK; Bell AK; Pringle MA; Villadsen R; Petersen OW; Sauter G; Bryson G; Mallon EA; Gusterson BA
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6872-9. PubMed ID: 16203777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis.
    Shen D; Nooraie F; Elshimali Y; Lonsberry V; He J; Bose S; Chia D; Seligson D; Chang HR; Goodglick L
    Hum Pathol; 2006 Dec; 37(12):1583-91. PubMed ID: 16949910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
    Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
    Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
    Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
    Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
    Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
    Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Brca1 and splice variant Brca1delta11 RNA levels in mouse mammary gland during normal development and tumorigenesis.
    Mixon M; Kittrell F; Medina D
    Oncogene; 2000 Nov; 19(46):5237-43. PubMed ID: 11077440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
    Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
    Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
    Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
    Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression.
    Manuylov NL; Smagulova FO; Tevosian SG
    Oncogene; 2007 Aug; 26(36):5204-13. PubMed ID: 17310981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
    Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
    Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer.
    Chang H; Mohabir N; Done S; Hamel PA
    J Clin Pathol; 2009 Oct; 62(10):908-14. PubMed ID: 19783719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
    Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
    Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
    Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Bergh J; Isola J
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4185-91. PubMed ID: 16857790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.
    Diallo R; Ting E; Gluz O; Herr A; Schütt G; Geddert H; Mohrmann S; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2006; 90():177-85. PubMed ID: 17867595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.